Effects of Carbamazepine on liver markers of Epileptics in Ogun State, Nigeria
Keywords:
Carbamazepine, Epilepsy, Hepatic EnzymesAbstract
Epilepsy is one of the commonest neurological diseases caused by an abnormal electrical discharge of brain neurons. Carbamazepine (CBZ) is widely used for the treatment of epilepsy. However, despite its use, it is not without effects on biochemical parameters. This study evaluated the effects of carbamazepine on plasma biochemical parameters in epileptics. Epileptics (n = 100) with different seizure types and age 18 – 50 years from Out Patient Clinic (OPC) in Neuropsychiatric Hospital, Abeokuta, Nigeria and sex-matched control (n = 100) from Federal University of Agriculture, Abeokuta were used. These epileptics were on CBZ for ≥ 6 months. Biochemical parameters such as
Aspartate transaminase (AST), Alanine transaminase (ALT), Alkaline phosphatase (ALP), Lactate dehydrogenase (LDH) and Gamma Glutamyl Transferase (GGT) were determined in plasma. The results revealed that epilepsy is common in male than female subjects. By sex, AST, GGT and LDH increased significantly (p<0.05) by 18%, 30% and 2fold in male and 24%, 42% and 1fold in female epileptics compared to their respective controls. By age, GGT increased significantly (p<0.05) in subjects between 18 – 20years, and 31- 40 years as compared to the control. LDH activity also increased significantly (p<0.05) between 18 – 20 years in epileptics compared to control. Based on seizure types, ALT activity increased significantly in male with focal seizure (28. 15 ± 5.28 U/L) compared with male generalized seizure (22.47 ± 2.1.70 U/L) and unclassified seizure (19.58 ± 3.44 U/L). It is concluded that treatment with carbamazepine for at least six months causes an alteration in the plasma liver enzymes of epileptic subjects.
References
1. Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, Engel Jr J, Forsgren L, French JA, Glynn M, Hesdorffer DC. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014 Apr;55(4):475-82.
2. Laxer KD, Trinka E, Hirsch LJ, Cendes F, Langfitt J, Delanty N, Resnick T, Benbadis SR. The consequences of refractory epilepsy and its treatment. Epilepsy & behavior. 2014 Aug 1;37:59-70.
3. Guerreiro CA. Epilepsy: Is there hope?. Indian Journal of Medical Research. 2016 Nov 1;144(5):657-60.
4. Sloviter RS, Bumanglag AV. Defining “epileptogenesis” and identifying “antiepileptogenic targets” in animal models of acquired temporal lobe epilepsy is not as simple as it might seem. Neuropharmacology. 2013 Jun 1;69:3-15.
5. Pitkänen A, Lukasiuk K. Molecular and cellular basis of epileptogenesis in symptomatic epilepsy. Epilepsy & behavior. 2009 Jan 1;14(1):16-25.
6. Reddy DS. Neuroendocrine aspects of catamenial epilepsy. Hormones and behavior. 2013 Feb 1;63(2):254-66.
7. Bar-Klein G, Lublinsky S, Kamintsky L, Noyman I, Veksler R, Dalipaj H, Senatorov Jr VV, Swissa E, Rosenbach D, Elazary N, Milikovsky DZ. Imaging blood–brain barrier dysfunction as a biomarker for epileptogenesis. Brain. 2017 Jun 1;140(6):1692-705.
8. Aroniadou-Anderjaska V, Fritsch B, Qashu F, Braga MF. Pathology and pathophysiology of the amygdala in epileptogenesis and epilepsy. Epilepsy research. 2008 Feb 1;78(2-3):102-16.
9. Ashrafi MR, Shams S, Nouri M, Mohseni M, Shabanian R, Yekaninejad MS, Chegini N, Khodadad A, Safaralizadeh R. A probable causative factor for an old problem: selenium and glutathione peroxidase appear to play important roles in epilepsy pathogenesis. Epilepsia. 2007 Sep;48(9):1750-5.
10. Löscher W, Brandt C. Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research. Pharmacological reviews. 2010 Dec 1;62(4):668-700.
11. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984. Epilepsia. 1993 May;34(3):453-8.
12. Ambali S. Heamatobiochemical Alterations Induced by Carbamazepine and Phenytoin: Mini Review. Biochemistry & Pharmacology: Open Access. 2016 Jan 1.
13. Porter RJ, Meldrum BS. Antiseizure drugs. Basic and clinical pharmacology. 2001;2018:413-23.
14. Zehnder J, Katzung SM, Trevor A. Basic and clinical pharmacology. McGraw-Hill Medical, New York; 2009.
15. Schwarz A, Strakos C, Weihrich R. A brief review on carbamazepine: history, pharmacological properties and environmental impact. 2021
16. Müller P, Draguhn A, Egorov AV. Persistent sodium currents in neurons: potential mechanisms and pharmacological blockers. Pflügers Archiv-European Journal of Physiology. 2024 Oct;476(10):1445-73.
17. Patsalos PN, Fröscher W, Pisani F, Van Rijn CM. The importance of drug interactions in epilepsy therapy. Epilepsia. 2002 Apr;43(4):365-85.
18. Zaccara G, Perucca E. Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. Epileptic Disorders. 2014 Dec;16(4):409-31.
19. Salawu F, Danburam A. Hyponatraemia during low-dose carbamazepine therapy. Annals of African Medicine. 2007;6(4).
20. Swann AC. Major system toxicities and side effects of anticonvulsants. Journal of Clinical Psychiatry. 2001 Jan 1;62(14):16-21.
21. Reitman S, Frankel S. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. American journal of clinical pathology. 1957 Jul 1;28(1):56-63.
22. Persijn JP, van der Slik W. More on serum enzymes in cancer patients. Clinical Chemistry. 1978 Apr 1;24(4):727-8.
23. Mintzer S, Skidmore CT, Abidin CJ, Morales MC, Chervoneva I, Capuzzi DM, Sperling MR. Effects of antiepileptic drugs on lipids, homocysteine, and C‐reactive protein. Annals of neurology. 2009 Apr;65(4):448-56.
24. Mintzer S. Metabolic consequences of antiepileptic drugs. Current opinion in neurology. 2010 Apr 1;23(2):164-9.
25. Bhosale UA, Loharkar NR, Yegnanarayan R, Quraishi N. Study of effects of antiepileptic therapy on various biochemical and hematological parameters patients suffering of epilepsy. Int J Basic Clin Pharmacol. 2014 Jan;3(1):79-85.
26. Mathew G, Lincy J, Preethi CJ. A review article on assessing the effect of antiepileptics and statins on liver enzymes in epileptic patients. The Pharma Innovation. 2016 Mar 1;5(3, Part A):11.
27. Mahgoub A, Abdoun M, Azam S, Babiker R. Effect of Carbamazepine and Sodium Valproate on Liver Enzymes of Epileptic Children. Dr. Sulaiman Al Habib Medical Journal. 2020 Sep;2(3):123-7.
28. Hadzagic-Catibusic F, Hasanbegovic E, Melunovic M, Zubcevic S, Uzicanin S. Effects of carbamazepine and valproate on serum aspartate aminotransferase, alanine aminotransferase and gamma—Glutamyltransferase in children. Med Arch. 2017; 71(4): 239–242.
29. Yoshimura Y, Hara K, Akaza M, Ohta K, Sumi Y, Inaji M, et al. Effects of antiepileptic monotherapy on hematological and biochemical parameters. Epilepsy Seizure. 2019; 11: 1–13.
30. Cho EJ, Jeong SM, Chung GE, Yoo JJ, Cho Y, Lee K, et al. Gamma-glutamyl transferase and risk of all-cause and disease-specific mortality: a nationwide cohort study. Sci Rep. 2023; 13(1):1751.
31. Serdaroglu F, Koca T, Dereci S, Akcam M. The etiology of hypertransaminasemia in Turkish children. Bosnian Journal of basic medical sciences. 2016 May;16(2):151.
32. Aliyu H, Ayo JO, Ambali SF, Zezi AU. Effects of administration of carbamazepine and/or phenytoin on serum biochemical parameters in Wistar rats. African Journal of Pharmacy and Pharmacology. 2013;7(23):1585-91.
33. Ahmed SN, Siddiqi ZA. Antiepileptic drugs and liver disease. Seizure. 2006 Apr 1;15(3):156-64.
34. Amhimmid FA, Alfazzani FS, Alzehawi SM, Bashoon SS. Biochemical side effect of antiepileptic drugs on liver enzymes, lipid profile and haematological profile in epileptic pediatric patients. Scholars Journal of Applied Medical Sciences. 2024 Aug;8:935-42.
35. Hussein RR, Soliman RH, Ali AM, Tawfeik MH, Abdelrahim ME. Effect of antiepileptic drugs on liver enzymes. Beni-Suef University Journal of Basic and Applied Sciences. 2013 Mar 1;2(1):14-9.
36. Naithani M, Chopra S, Somani BL, Singh RK. Studies on adverse metabolic effects of antiepileptics and their correlation with blood components. Current Neurobiology. 2010;1(2):117-20.
37. Björnsson E. Hepatotoxicity associated with antiepileptic drugs. Acta Neurologica Scandinavica. 2008 Nov;118(5):281-90.
38. Merete A, Brechan L, TaubØll E, Jemtland R, Godang K, Bollerslev J, Gjer-stad L. The effect of chronic carbamazepine treatment in postmenopausal women. Epilepsia. 2005;46:167-92.
